Emerald Acquisition’s Kyntra Bio KYNB Stock Holding History

Emerald Acquisition’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$270K	Buy	+522	New	+$246K	﹤0.01%	2622

Other funds holding KYNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Emerald Acquisition's KYNB Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Kyntra Bio (KYNB) in Q3 2016: 522 shares worth $270K. The stake represents ﹤0.01% of the portfolio and ranks #2622 among its holdings.

133 funds tracked by Wall St. Rank hold KYNB as of Q3 2016.

Emerald Acquisition held 522 shares of Kyntra Bio worth $270K as of Q3 2016.
Kyntra Bio was a new Emerald Acquisition position in Q3 2016.
Kyntra Bio made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2622 holding.
133 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.